Radiopharm Theranostics (ASX:RAD) ROCE %: -48.71% (As of Jun. 2025)


What is Radiopharm Theranostics ROCE %?

Radiopharm Theranostics ASX:RAD -5.00% ROCE % is -48.71% as of Jun. 2025. The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Radiopharm Theranostics's annualized ROCE % for the quarter that ended in Jun. 2025 was -48.71%.

Radiopharm Theranostics  (ASX:RAD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Radiopharm Theranostics ROCE % Related Terms

Radiopharm Theranostics ROCE % Historical Data

* Premium members only.

The historical data trend for Radiopharm Theranostics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radiopharm Theranostics ROCE % Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
ROCE %
-27.74 -50.26 -81.27 -60.59

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
ROCE % Get a 7-Day Free Trial -72.83 -97.88 -82.70 -49.95 -48.71

Radiopharm Theranostics ROCE % Calculation

Radiopharm Theranostics's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=-38.174/( ( (72.036 - 17.576) + (86.482 - 14.933) )/ 2 )
=-38.174/( (54.46+71.549)/ 2 )
=-38.174/63.0045
=-60.59 %

Radiopharm Theranostics's ROCE % of for the quarter that ended in Jun. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2025 )  (Q: Dec. 2024 )(Q: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2025 )  (Q: Dec. 2024 )(Q: Jun. 2025 )
=-36.738/( ( (92.452 - 13.146) + (86.482 - 14.933) )/ 2 )
=-36.738/( ( 79.306 + 71.549 )/ 2 )
=-36.738/75.4275
=-48.71 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -48.71% mean?
Radiopharm Theranostics (ASX:RAD) has a ROCE % of -48.71% as of Jun. 2025.
Is Radiopharm Theranostics' ROCE % too high?
Radiopharm Theranostics' current ROCE % is -48.71%.
How does Radiopharm Theranostics' ROCE % compare to VRTX and REGN?
Radiopharm Theranostics' ROCE % of -48.71% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Radiopharm Theranostics's current ROCE % is -48.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (ASX:RAD) has a current ROCE % of -48.71%. The current ROCE % is -48.71%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Radiopharm Theranostics (ASX:RAD), the current ROCE % is -48.71% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radiopharm Theranostics Business Description

Other Exchanges RADX:USA
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.